Last reviewed · How we verify
Pizensy (LACTITOL)
Pizensy (LACTITOL) is an osmotic laxative developed by Braintree Labs, currently owned by the same company. It is a small molecule drug approved by the FDA in 2020 for the treatment of chronic idiopathic constipation. Pizensy works by drawing water into the intestines to soften and stimulate bowel movements. As a patented product with no generic manufacturers, its commercial status is unique. Key safety considerations include its short half-life of 2.4 hours.
At a glance
| Generic name | LACTITOL |
|---|---|
| Sponsor | Braintree Labs |
| Drug class | Osmotic Laxative |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
| First approval | 2020 |
Approved indications
- Chronic idiopathic constipation
Common side effects
Key clinical trials
- BLI400-302: A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults (PHASE3)
- A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults (PHASE3)
- Study of Efficacy and Safety of Canakinumab in Japanese Patients With AOSD (PHASE3)
- Artificial Cycle With or Without GnRH Agonist Pre-treatment for Frozen Embryo Transfer in Adenomyosis Patients (NA)
- An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden
- CINC424A2X01B Rollover Protocol (PHASE4)
- Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments (PHASE1,PHASE2)
- Secukinumab Open Label Roll-over Extension Protocol (PHASE4)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pizensy CI brief — competitive landscape report
- Pizensy updates RSS · CI watch RSS
- Braintree Labs portfolio CI